...
首页> 外文期刊>Oncology reports >Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells
【24h】

Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells

机译:组蛋白脱乙酰基酶抑制剂十肽和5-氟尿嘧啶的组合上调人类结肠癌HCT-116细胞中的主要组织相容性复合物II类和p21基因并激活caspase-3 / 7

获取原文
获取原文并翻译 | 示例
           

摘要

Epigenetic anticancer drugs such as histone deacetylase (HDAC) inhibitors have been combined with existing anticancer drugs for synergistic or additive effects. In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability. Exposure to a combination of 5-FU (1.75 mu M) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7. Microarray and subsequent gene ontology analyses revealed that compared to 5-FU or depsipeptide alone, the combination treatment of 5-FU and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase-3/7 activation. These analyses indicated marked upregulation of antigen processing and presentation of peptide or polysaccharide antigen via major histocompatibility complex (MHC) class (GO:0002504) and MHC protein complex (GO:0042611). Compared with vehicle controls, the cells treated with the combination of 5-FU and depsipeptide showed marked induction (3- to 8.5-fold) of expression of MHC class II genes, but not of MHC class I genes. Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of 5-FU and depsipeptide. These results may indicate a closer relationship between elevation of MHC class II expression and cellular apoptosis induced by the combination of depsipeptide and 5-FU. To the best of our knowledge, this is the first study to report that the combination of 5-FU and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression.
机译:表观遗传抗癌药(例如组蛋白脱乙酰基酶(HDAC)抑制剂)已与现有抗癌药结合使用,以产生协同作用或累加作用。在本研究中,我们发现使用HCT-116,HT29和SW48细胞通过HDAC抑制剂,一种非常低浓度的depsipeptide可以增强人体内结肠癌细胞5-氟尿嘧啶(5-FU)的抗肿瘤活性。抑制菌落形成能力或细胞活力。暴露于5-FU(1.75μM)和1 nM脱肽肽的组合中24和48小时会导致激活的caspase-3 / 7增加3到4倍,而单独的5-FU无法激活caspase- 3/7。基因芯片和随后的基因本体分析表明,与单独使用5-FU或双倍肽相比,联合使用5-FU和双倍肽可上调与细胞死亡和凋亡过程相关的基因,从而抑制菌落形成和抑制caspase-3 / 7活化。这些分析表明抗原加工显着上调,并通过主要组织相容性复合物(MHC)类(GO:0002504)和MHC蛋白复合物(GO:0042611)呈递肽或多糖抗原。与媒介物对照相比,用5-FU和十肽联合处理的细胞显示出明显的诱导(3至8.5倍)表达MHC II类基因,但不诱导MHC I类基因。此外,我们对基因表达的全球分析集中于与MHC II类基因的分子调控有关的基因,结果表明,5-FU和depsipeptide组合后促凋亡的PCAF和CIITA增强。这些结果可能表明II类MHC表达的升高与由十肽和5-FU的组合诱导的细胞凋亡之间存在更紧密的关系。据我们所知,这是第一个报道5-FU和二肽结合在一起以协同方式诱导人类结肠癌细胞凋亡并诱导MHC II类基因表达的研究。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号